pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
23d
Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing
fiercebiotech
23d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
24d
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
endpoints
24d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
24d
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
endpoints
25d
STAT+: The ESMO presentation everyone’s been waiting for
stat
25d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
26d
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
stat
26d
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
stat
26d
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
stat
26d
Q&A: Bristol Myers' Lynelle Hoch on autoimmune CAR-T safety challenges
endpoints
26d
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
biospace
26d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
26d
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
endpoints
26d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
26d
Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
endpoints
26d
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
stat
26d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
27d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
28d
Critical decisions that spurred these 40 Under 40 winners to success
biospace
28d
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
biospace
28d
Astellas links up with AI Proteins in $400M computational drug discovery deal
fiercebiotech
29d
The 6 biggest crossover rounds in biopharma history
biospace
29d
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
29d
BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up
fiercebiotech
Oct 19, 26
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
Oct 15, 26
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
Oct 15, 26
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
fiercebiotech
Oct 14, 26
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
Oct 13, 26
BioNTech mRNA cancer immunotherapy misses first objective in key study
biopharma dive
← prev
page 3 of 12
next →